Neither vaginal nor buccal administration of 800 μg misoprostol alters mucosal and systemic immune activation or the cervicovaginal microbiome: a pilot study.

Kalams SA, Rogers LM, Smith RM, Barnett L, Crumbo K, Sumner S, Prashad N, Rybczyk K, Milne G, Dowd SE, Chong E, Winikoff B, Aronoff DM
Eur J Contracept Reprod Health Care. 2016 21 (6): 436-442

PMID: 27636701 · PMCID: PMC5589076 · DOI:10.1080/13625187.2016.1229765

MeSH Terms (16)

Abortifacient Agents, Nonsteroidal Administration, Buccal Administration, Intravaginal Cervix Uteri Cross-Over Studies Elafin Enzyme-Linked Immunosorbent Assay Female Humans Immune System Lymphocytes Microbiota Misoprostol Pilot Projects United States Vagina

Connections (1)

This publication is referenced by other Labnodes entities: